18 posts in this category
California AB-1990 would raise ingredient, record-keeping, and advertising rules for compounded GLP-1 medications. What it could mean for you.
What are peptides and how do they differ from GLP-1 medications? A plain-language guide to BPC-157, CJC-1295, ipamorelin, and more.
A calm, plain-language explainer on SNAC, the absorption helper in oral semaglutide pills, and what the new 2026 study actually found.
A plain-language side-by-side of Foundayo and the Wegovy pill. Dosing, weight loss, side effects, and cost compared for 2026.
FDA statements, tariffs, and lawsuits have compounded GLP-1 patients' worries. Here is what is changing, what is not, and what it means for your price
Wegovy HD (7.2 mg) is now FDA-approved with 20.7% average weight loss. Learn about results, effects, availability, and how it compares to Zepbound.
FDA warned 30 telehealth companies over GLP-1 marketing claims. Learn what changed, why compounding is not going away, and what to look for.
The FDA warned Novo Nordisk for not reporting deaths and serious side effects tied to its GLP-1 medications. Here is what happened.
Hearing new GLP-1 names? Learn why language changed, what stayed the same, and how to tell if your medication actually changed.
Learn how to identify fake Ozempic, check packaging and lot numbers, and avoid online GLP-1 scams. Simple safety tips for families.
What does GLP-1/GIP mean? Learn how dual GIP/GLP-1 medications differ from GLP-1 drugs and why terminology is changing.
Research GLP-1 peptides are often sold online outside the medical system. Learn what they are, why they’re risky, and how to spot grey-market products.
FDA review finds no increased suicide risk with GLP-1 medications and is asking for related label warnings to be removed.
See how states, Medicare, Medicaid, and employer plans are handling GLP-1 coverage changes in 2026 and what it means for your insurance.
FDA: “many of the adverse events reported for compounded versions appear to be consistent with adverse events for the FDA‑approved products.”
We’ve all been hearing about the shortage of tirzepatide or semaglutide, but what is a shortage? How does it impact compounding?
The FDA has ended the shortage for tirzepatide, essential copy compounding ends on Feb 18 and March 19
November 21 joint status report on the OFA vs FDA lawsuit over compounded tirzepatide availability and the FDA's ongoing reevaluation.
